Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

被引：0
|
作者：
Hizal, Mutlu [1 ]
Sendur, Mehmet A. N. [2 ]
Yalcin, Bulent [2 ]
机构：
[1] Ankara City Hosp, Ankara, Turkey
[2] Yildirim Beyazit Univ, Ankara, Turkey
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：694 / 694
页数：1
相关论文
共 50 条
  • [11] Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
    Han, Ji Won
    Jang, Jeong Won
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [12] Therapy with Atezolizumab and Bevacizumab prolongs Life of Patients with hepatocellular Carcinoma
    Kessing, Richard
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (09):
  • [13] Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma
    Ha, Yeonjung
    Cheon, Jaekyung
    Hwang, Seong Gyu
    Chon, Hong Jae
    JOURNAL OF HEPATOLOGY, 2021, 75 : S526 - S527
  • [14] Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
    Brackenier, Cedric
    Kinget, Lisa
    Cappuyns, Sarah
    Verslype, Chris
    Beuselinck, Benoit
    Dekervel, Jeroen
    CANCERS, 2023, 15 (02)
  • [15] A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
    Watanabe, Yukinobu
    Ogawa, Masahiro
    Tamura, Yu
    Suda, Seiichiro
    Kaneko, Masahiro
    Kumagawa, Mariko
    Hirayama, Midori
    Matsumoto, Naoki
    Yamamoto, Toshiki
    Moriyama, Mitsuhiko
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2021, 9
  • [16] Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?
    Kao, Wei-Yu
    Su, Chien-Wei
    LIVER INTERNATIONAL, 2022, 42 (12) : 2597 - 2598
  • [17] Histologic predictors of response to atezolizumab and bevacizumab in hepatocellular carcinoma biopsies
    Sayadi, A.
    Bouattour, M.
    Burgio, M. Dioguardi
    Albuquerque, M.
    Paradis, V.
    Beaufrere, A.
    VIRCHOWS ARCHIV, 2024, 485 : S70 - S71
  • [18] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Ahmed, Faiza
    Onwumeh-Okwundu, Jennifer
    Yukselen, Zeynep
    Endaya Coronel, Maria-Kassandra
    Zaidi, Madiha
    Guntipalli, Prathima
    Garimella, Vamsi
    Gudapati, Sravya
    Mezidor, Marc Darlene
    Andrews, Kim
    Mouchli, Mohamad
    Shahini, Endrit
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (11) : 1813 - 1832
  • [19] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Faiza Ahmed
    Jennifer Onwumeh-Okwundu
    Zeynep Yukselen
    Maria-Kassandra Endaya Coronel
    Madiha Zaidi
    Prathima Guntipalli
    Vamsi Garimella
    Sravya Gudapati
    Marc Darlene Mezidor
    Kim Andrews
    Mohamad Mouchli
    Endrit Shahini
    World Journal of Gastrointestinal Oncology, 2021, 13 (11) : 1813 - 1832
  • [20] Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
    Yano, Yoshihiko
    Yamamoto, Atsushi
    Mimura, Takuya
    Kushida, Saeko
    Hirohata, Seiya
    Yoon, Seitetsu
    Hirano, Hirotaka
    Kim, Soo Ki
    Hatazawa, Yuri
    Momose, Kenji
    Hayashi, Hiroki
    Kado, Takuo
    Nishi, Katsuhisa
    Tanaka, Hidenori
    Matsuura, Takanori
    Yoshida, Ryutaro
    Asaji, Naoki
    Yasutomi, Eiichiro
    Shiomi, Yuuki
    Minami, Akihiro
    Komatsu, Shohei
    Fukumoto, Takumi
    Ueda, Yoshihide
    Kodama, Yuzo
    JGH OPEN, 2023, 7 (07): : 476 - 481
12345